University of Wisconsin–Madison-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 8, Núm. 1

  3. If You're Not Confused, You're Not Paying Attention: Ochrobactrum Is Not Brucella

    Journal of clinical microbiology, Vol. 61, Núm. 8, pp. e0043823

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2018

  1. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

2017

  1. Complexity of complement resistance factors expressed by acinetobacter baumannii needed for survival in human serum

    Journal of Immunology, Vol. 199, Núm. 8, pp. 2803-2814

  2. Recent progress in translational research on neurovascular and neurodegenerative disorders

    Restorative Neurology and Neuroscience, Vol. 35, Núm. 1, pp. 87-103

2016

  1. An international consensus definition of the wish to hasten death and its related factors

    PLoS ONE, Vol. 11, Núm. 1

  2. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

2011

  1. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer

    Breast Cancer Research, Vol. 13, Núm. 1

2009

  1. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes

    Journal of Endocrinology, Vol. 203, Núm. 1, pp. 99-110